Showing 7041-7050 of 10171 results for "".
- Resident Grants Available for Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20140701-resident_grants_available_for_cosmetic_surgery_forum/2459183/The Cosmetic Surgery Forum 2014, jointly sponsored by the Dulaney Foundation, Practical Dermatology® magazine and Cosmetic Surgery Forum, LLC, will take place December 3 through December 6, 2014 at The Palazzo Hotel Resort & Casino i
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- FDA Issues Guidance Supporting the Responsible Development of Nanotechnology Productshttps://practicaldermatology.com/news/20140625-fda_issues_guidance_supporting_the_responsible_development_of_nanotechnology_products/2459190/Three final guidances and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products. Nanotechnology is an emerging technology allowing scientists to create, explore, and
- AMBI® Skincare Names Model Search Winnerhttps://practicaldermatology.com/news/20140623-ambi_skincare_names_model_search_winner/2459194/Charnee Long, 21, is the Grand Prize Winner of the first-ever nationwide AMBI® Model Search. Charnee was one of 10 finalists selected from a pool of more than 6,099 entrants. She will be featured in a national print campaign, receiving a three day/two night trip to New York City for a pro
- South Beach Symposium Debuts New Host Hotelhttps://practicaldermatology.com/news/20140623-south_beach_symposium_debuts_new_host_hotel/2459198/The 13th annual meeting of the South Beach Symposium moves to the Fontainebleau Hotel in Miami Beach, February 12-16, 2015. Faculty for the event have been announced on the SBS website. There are non-overlapping CME tracks: the Mas
- Celsus Therapeutics Receives Ministry of Health of Israel Approval to Conduct Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/20140617-a_new_class_of_treatment_can_to_be_used_for_atopic_dermatitis/2459202/Celsus Therapeutics Plc received approval from Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients. The Company plans to conduct the study in five to six centers in Israel as well as Argentina. They plan to enroll 80 pediatric patient
- Spain's LETI Laboratories Launches Leading Atopic Skincare Line to U.S. Markethttps://practicaldermatology.com/news/20140617-spains_leti_laboratories_launches_leading_atopic_skincare_line_to_us_market/2459203/DermWORX Professional Skincare and LETI Laboratories, headquartered in Barcelona, Spain, will launch a series of top European dermatological products in the United States. The series includes: LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. heal
- Provectus Biopharmaceuticals will discuss outline of Phase 3 Clinical Trial Of PV-10 To Treat Melanoma on Conference Callhttps://practicaldermatology.com/news/20140612-provectus_biopharmaceuticals_will_discuss_outline_of_phase_3_clinical_trial_of_pv-10_to_treat_melanoma_on_conference_call/2459208/Provectus Biopharmaceuticals, Inc. has announced that it will hold a conference call on Thursday, June 19, 2014, at 4 pm Eastern Daylight Time. Management will discuss the outline of the Company's proposed Phase 3 study of PV-10 in the treatment of melanoma, developments in the use of PV-
- Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosishttps://practicaldermatology.com/news/20140609-valeant_pharmaceuticals_announces_fda_approval_of_jublia_for_the_treatment_of_onychomycosis/2459213/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole
- Cosmetic Surgery Forum Unveils 2014 Agendahttps://practicaldermatology.com/news/20140606-cosmetic_surgery_forum_unveils_2014_agenda/2459216/The agenda for the 2014 Cosmetic Surgery Forum was recently unveiled. The meeting will take place from December 3 through December 6 at the Palazzo Casino and Resort in Las Vegas, NV. Under course director Joel Schlessinger, MD, this year's meeting will include sessions on cosmetic treatments for me